Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:PTGXNASDAQ:RARENYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$41.52-1.2%$29.96$16.50▼$43.58$3.62BN/A49,642 shs9,149 shsPTGXProtagonist Therapeutics$49.71-0.3%$49.51$32.50▼$60.60$3.08B2.26841,043 shs177,348 shsRAREUltragenyx Pharmaceutical$39.27-0.9%$36.75$29.59▼$60.37$3.71B0.26838,472 shs372,642 shsZYMEZymeworks$12.93-1.1%$12.23$8.83▼$17.70$899.63M1.19581,236 shs92,708 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.89%+6.75%+48.13%+116.03%+4,203,999,900.00%PTGXProtagonist Therapeutics-2.60%-9.77%-8.29%+19.68%+47.89%RAREUltragenyx Pharmaceutical+1.07%+8.94%+6.56%+27.53%-3.11%ZYMEZymeworks+1.91%+4.22%+3.81%+31.99%+47.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics2.0636 of 5 stars3.51.00.00.02.52.50.0RAREUltragenyx Pharmaceutical3.935 of 5 stars3.51.00.03.82.22.50.6ZYMEZymeworks2.0486 of 5 stars3.51.00.00.01.83.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/APTGXProtagonist Therapeutics 3.00Buy$66.1032.57% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$87.00120.15% UpsideZYMEZymeworks 2.90Moderate Buy$21.0061.82% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, RARE, PTGX, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$13.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M26.90N/AN/A$0.48 per share86.42PTGXProtagonist Therapeutics$434.43M7.11$4.41 per share11.30$11.33 per share4.40RAREUltragenyx Pharmaceutical$560.23M6.67N/AN/A$2.76 per share14.32ZYMEZymeworks$93.38M9.67N/AN/A$6.63 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/APTGXProtagonist Therapeutics$275.19M$0.7566.48N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest ZYME, RARE, PTGX, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025PTGXProtagonist Therapeutics-$0.53N/AN/AN/A$8.32 millionN/A5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26PTGXProtagonist TherapeuticsN/A17.2517.26RAREUltragenyx PharmaceuticalN/A2.402.24ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/APTGXProtagonist Therapeutics98.63%RAREUltragenyx Pharmaceutical97.67%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/APTGXProtagonist Therapeutics4.90%RAREUltragenyx Pharmaceutical5.50%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/APTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableZYME, RARE, PTGX, and AAPG HeadlinesRecent News About These CompaniesZymeworks (NYSE:ZYME) Receives "Neutral" Rating from HC WainwrightJuly 5 at 2:13 AM | americanbankingnews.comZymeworks (NYSE:ZYME) Given "Neutral" Rating at HC WainwrightJuly 3, 2025 | marketbeat.comZymeworks Amends Warrant Agreement with EcoR1 CapitalJune 27, 2025 | tipranks.comZYME - Zymeworks Inc Registered Shs Dividends - MorningstarJune 27, 2025 | morningstar.comMCompanies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comAll You Need to Know About Zymeworks (ZYME) Rating Upgrade to BuyJune 20, 2025 | zacks.comRhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)June 20, 2025 | marketbeat.comDuncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)June 19, 2025 | marketbeat.comZymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500June 18, 2025 | kalkinemedia.comKSG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)June 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)June 15, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?June 13, 2025 | marketbeat.comZymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)June 12, 2025 | seekingalpha.comBank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)June 12, 2025 | marketbeat.comWall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?June 4, 2025 | zacks.comZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2, 2025 | msn.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comEChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comPZymeworks’ zanidatamab approved in ChinaMay 30, 2025 | thepharmaletter.comTZymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To BudgeMay 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Why Qualcomm’s Latest Price Target Can't Be IgnoredBy Sam Quirke | June 24, 2025View Why Qualcomm’s Latest Price Target Can't Be IgnoredTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalTop 5 Undervalued Dividend Stocks With Strong Payout PotentialBy Ryan Hasson | July 7, 2025View Top 5 Undervalued Dividend Stocks With Strong Payout PotentialZYME, RARE, PTGX, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$41.52 -0.52 (-1.24%) As of 12:18 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Protagonist Therapeutics NASDAQ:PTGX$49.71 -0.16 (-0.32%) As of 12:57 PM EasternProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Ultragenyx Pharmaceutical NASDAQ:RARE$39.27 -0.34 (-0.86%) As of 12:57 PM EasternUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Zymeworks NYSE:ZYME$12.93 -0.15 (-1.15%) As of 12:58 PM EasternZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
